Journal of Neural Transmission

, Volume 123, Issue 5, pp 533–540 | Cite as

Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting

  • Katja Kollewe
  • Claus M. Escher
  • Dirk U. Wulff
  • Davood Fathi
  • Lejla Paracka
  • Bahram Mohammadi
  • Matthias Karst
  • Dirk Dressler
Neurology and Preclinical Neurological Studies - Original Article

Abstract

Botulinum toxin was shown to be effective in treatment of chronic migraine. We wanted to explore its efficacy and tolerability in chronic application under real-life conditions. For this, 27 consecutive patients (age 45.6 ± 10.8 years, 25 females, 2 males) received altogether 176 injection series (IS) with 189.7 ± 45.8MU onabotulinumtoxinA (Botox®) according to the PREEMPT scheme. During the study period altogether 6.5 ± 2.9 (min 4, max 13) IS were applied per patient (total treatment time of 73.1 ± 36.9 weeks). 96 % of the patients reported benefit. Monthly headache days were reduced from 18.9 ± 3.9 to 8.7 ± 4.5 (p < 0.001, −53.7 %), migraine days from 16.8 ± 4.9 to 7.4 ± 4.6 (p < 0.001, −55.1 %), autonomic days from 8.6 ± 7.5 to 2.7 ± 4.2 (p < 0.001, −71.9 %) and medication days from 14.2 ± 4.6 to 8.3 ± 4.2 (p < 0.001, −71.1 %). Health-related quality of life improved by 0.6–1.5 standard deviations (SD) (Short Form Health Survey), migraine-related quality of life by 1.4–2.0 SD (Migraine-Specific Quality of Life Questionnaire) and by 1.9 SD (Headache Impact Test), depression by 1.1 SD (Beck Depression Inventory). Subjective global clinical improvement was 2.6 ± 0.6 (Global Clinical Improvement Scale). All improvements were stable throughout the entire study period. Adverse effects were infrequent, mild and transient. Botulinum toxin provides highly effective and safe long-term treatment of chronic migraine.

Keywords

Botulinum toxin Botox® OnabotulinumtoxinA Chronic migraine Long-term treatment Real-life setting 

Notes

Compliance with ethical standards

Conflict of interest

KK and BM received travel grants and honoraria for lectures from Allergan, Ipsen and Merz. LP received travel grants from Ipsen and Merz. MK received honoraria for lectures from Allergan. DD received honoraria for consultations from Allergan, Bayer, Eisai, IAB- Interdisciplinary Working Group for Movement Disorders, Ipsen, Merz, Syntaxin and UCB. He is shareholder of Allergan and holds several patents on Botulinum Toxins. CE, DUW and DF state that they have no conflict of interest.

References

  1. Aoki KR (2003) Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 43(Suppl 1):S9–S15CrossRefPubMedGoogle Scholar
  2. Aurora S et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 30:793–803. doi:10.1177/0333102410364676 CrossRefPubMedGoogle Scholar
  3. Aurora SK et al (2011) OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache J Head Face Pain 51:1358–1373. doi:10.1111/j.1526-4610.2011.01990.x CrossRefGoogle Scholar
  4. Aurora SK, Dodick DW, Diener HC, DeGryse RE, Turkel CC, Lipton RB, Silberstein SD (2014) OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program. Acta Neurol Scand 129:61–70. doi:10.1111/ane.12171 CrossRefPubMedPubMedCentralGoogle Scholar
  5. Bagley CL, Rendas-Baum R, Maglinte GA, Yang M, Varon SF, Lee J, Kosinski M (2012) Validating migraine-specific quality of life questionnaire v2.1 in episodic and chronic migraine. Headache J Head Face Pain 52:409–421. doi:10.1111/j.1526-4610.2011.01997.x CrossRefGoogle Scholar
  6. Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB (2004) Transformed migraine and medication overuse in a tertiary headache centre–clinical characteristics and treatment outcomes. Cephalalgia 24:483–490CrossRefPubMedGoogle Scholar
  7. Bigal ME, Serrano D, Reed M, Lipton RB (2008) Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 71:559–566. doi:10.1212/01.wnl.0000323925.29520.e7 CrossRefPubMedGoogle Scholar
  8. Binder W, Brin M, Blitzer A, Schoenrock L, Pogoda J (2000) Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 123:669–676. doi:10.1067/mhn.2000.110960 CrossRefPubMedGoogle Scholar
  9. Blumenfeld A, Silberstein SD, Dodick DW, Aurora SK, Turkel CC, Binder WJ (2010) Method of injection of OnabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program: October 2010. Headache J Head Face Pain 50:1406–1418. doi:10.1111/j.1526-4610.2010.01766.x CrossRefGoogle Scholar
  10. Blumenfeld A et al (2011) Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the international burden of migraine study (IBMS). Cephalalgia 31:301–315. doi:10.1177/0333102410381145 CrossRefPubMedGoogle Scholar
  11. Buse DC, Manack A, Serrano D, Turkel C, Lipton RB (2010) Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers. J Neurol Neurosurg Psychiatry 81:428–432. doi:10.1136/jnnp.2009.192492 CrossRefPubMedGoogle Scholar
  12. Buse DC, Manack AN, Fanning KM, Serrano D, Reed ML, Turkel CC, Lipton RB (2012) Chronic Migraine Prevalence. Headache J Head Face Pain 52:1456–1470. doi:10.1111/j.1526-4610.2012.02223.x CrossRefGoogle Scholar
  13. Cady RK, Schreiber CP, Porter JAH, Blumenfeld AM, Farmer KU (2011) A multi-center double-blind pilot comparison of OnabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache J Head Face Pain 51:21–32. doi:10.1111/j.1526-4610.2010.01796.x CrossRefGoogle Scholar
  14. Castillo J, Muñoz P, Guitera V, Pascual J (1999) Epidemiology of chronic daily headache in the general population. Headache J Head Face Pain 39:190–196CrossRefGoogle Scholar
  15. Cernuda-Morollon E, Ramon C, Larrosa D, Alvarez R, Riesco N, Pascual J (2014) Long-term experience with onabotulinumtoxinA in the treatment of chronic migraine: what happens after 1 year? Cephalalgia. doi:10.1177/0333102414561873 Google Scholar
  16. Cohen J (1992) A power primer. Psychol Bull 112:155–159CrossRefPubMedGoogle Scholar
  17. Conway S, Delplanche C, Crowder J, Rothrock J (2005) Botox therapy for refractory chronic migraine. Headache 45:355–357CrossRefPubMedGoogle Scholar
  18. Cui M, Khanijou S, Rubino J, Aoki KR (2004) Subcutaneous administration of botulinum toxin a reduces formalin-induced pain. Pain 107:125–133CrossRefPubMedGoogle Scholar
  19. Diener HC, Weimar C (2012) Therapie der Migräne. In: Leitlinien für Diagnostik und Therapie in der Neurologie. Thieme Verlag, StuttgartGoogle Scholar
  20. Diener HC, Bussone G, Van Oene J, Lahaye M, Schwalen S, Goadsby P, Group* T-M-S (2007) Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 27:814–823. doi:10.1111/j.1468-2982.2007.01326.x CrossRefPubMedGoogle Scholar
  21. Diener H et al (2010) OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30:804–814. doi:10.1177/0333102410364677 CrossRefPubMedGoogle Scholar
  22. Dodick D, Mauskop A, Elkind A, DeGryse R, Brin M, Silberstein S (2005) Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache 45:315–324CrossRefPubMedGoogle Scholar
  23. Dressler D, Tacik P, Adib Saberi F (2014) Botulinum toxin therapy of cervical dystonia: comparing onabotulinumtoxinA (Botox®) and incobotulinumtoxinA (Xeomin®). J Neural Transm 121:29–31. doi:10.1007/s00702-013-1076-z CrossRefPubMedPubMedCentralGoogle Scholar
  24. Durham PL, Cady R, Cady R (2004) Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 44:35–42. doi:10.1111/j.1526-4610.2004.04007.x (discussion 42–3) CrossRefPubMedGoogle Scholar
  25. Evers S, Rahmann A, Vollmer-Haase J, Husstedt IW (2002) Treatment of headache with botulinum toxin A—a review according to evidence-based medicine criteria. Cephalalgia 22:699–710CrossRefPubMedGoogle Scholar
  26. Finzi E, Rosenthal NE (2014) Treatment of depression with onabotulinumtoxinA: a randomized, double-blind, placebo controlled trial. J Psychiatr Res 52:1–6. doi:10.1016/j.jpsychires.2013.11.006 CrossRefPubMedGoogle Scholar
  27. Freitag FG, Diamond S, Diamond M, Urban G (2008) Botulinum toxin type A in the treatment of chronic migraine without medication overuse. Headache 48:201–209. doi:10.1111/j.1526-4610.2007.00963.x PubMedGoogle Scholar
  28. Guitera V, Munoz P, Castillo J, Pascual J (2002) Quality of life in chronic daily headache: a study in a general population. Neurology 58:1062–1065. doi:10.1212/wnl.58.7.1062 CrossRefPubMedGoogle Scholar
  29. Headache Classification Committee of the International Headache S (2013) The international classification of headache disorders, 3rd edition (beta version). Cephalalgia 33:629–808. doi:10.1177/0333102413485658 CrossRefGoogle Scholar
  30. Jackson JL, Kuriyama A, Hayashino Y (2012) Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults: a meta-analysis. Jama 307:1736–1745CrossRefPubMedGoogle Scholar
  31. Jhingran P, Osterhaus JT, Miller DW, Lee JT, Kirchdoerfer L (1998) Development and validation of the migraine-specific quality of life questionnaire. Headache J Head Face Pain 38:295–302CrossRefGoogle Scholar
  32. Katsarava Z, Buse DC, Manack AN, Lipton RB (2012) Defining the differences between episodic migraine and chronic migraine. Curr Pain Headache Rep 16:86–92. doi:10.1007/s11916-011-0233-z CrossRefPubMedPubMedCentralGoogle Scholar
  33. Khalil M, Zafar H, Quarshie V, Ahmed F (2014) Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, UK. J Headache Pain 15:54. doi:10.1186/1129-2377-15-54 CrossRefPubMedPubMedCentralGoogle Scholar
  34. Kollewe K, Mohammadi B, Dengler R, Dressler D (2010) Hemifacial spasm and reinnervation synkinesias: long-term treatment with either Botox® or Dysport®. J Neural Transm 117:759–763. doi:10.1007/s00702-010-0409-4 CrossRefPubMedGoogle Scholar
  35. Kollewe K, Mohammadi B, Kohler S, Pickenbrock H, Dengler R, Dressler D (2015) Blepharospasm: long-term treatment with either Botox(R), Xeomin(R) or Dysport(R). J Neural Transm 122:427–431. doi:10.1007/s00702-014-1278-z CrossRefPubMedGoogle Scholar
  36. Kosinski M et al (2003) A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res Int J Qual Life Asp Treat Care Rehabil 12:963–974CrossRefGoogle Scholar
  37. Kühner C, Bürger C, Keller F, Hautzinger M (2007) Reliabilität und Validität des revidierten Beck-Depressionsinventars (BDI-II): befunde aus deutschsprachigen Stichproben. Der Nervenarzt 78:651–656. doi:10.1007/s00115-006-2098-7 CrossRefPubMedGoogle Scholar
  38. Lipton RB et al (2011) OnabotulinumtoxinA improves quality of life and reduces impact of chronic migraine. Neurology 77:1465–1472. doi:10.1212/WNL.0b013e318232ab65 CrossRefPubMedGoogle Scholar
  39. Magalhães E, Menezes C, Cardeal M, Melo A (2010) Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine. Clin Neurol Neurosurg 112:463–466. doi:10.1016/j.clineuro.2010.02.004 CrossRefPubMedGoogle Scholar
  40. Magid M, Reichenberg JS, Poth PE, Robertson HT, LaViolette AK, Kruger TH, Wollmer MA (2014) Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry 75:837–844CrossRefPubMedGoogle Scholar
  41. Manack AN, Buse DC, Lipton RB (2011) Chronic Migraine: Epidemiology and Disease Burden. Curr Pain Headache Rep 15:70–78. doi:10.1007/s11916-010-0157-z CrossRefPubMedGoogle Scholar
  42. Matak I, Lackovic Z (2014) Botulinum toxin A, brain and pain. Prog Neurobiol 119–120:39–59. doi:10.1016/j.pneurobio.2014.06.001 CrossRefPubMedGoogle Scholar
  43. Mohammadi B, Kollewe K, Wegener M, Bigalke H, Dengler R (2009) Experience with long-term treatment with albumin-supplemented botulinum toxin type A. J Neural Transm 116:437–441. doi:10.1007/s00702-009-0200-6 CrossRefPubMedGoogle Scholar
  44. Natoli JL, Manack A, Dean B, Butler Q, Turkel CC, Stovner L, Lipton RB (2010) Global prevalence of chronic migraine: a systematic review. Cephalalgia 30:599–609. doi:10.1111/j.1468-2982.2009.01941.x PubMedGoogle Scholar
  45. Petri S, Tölle TT, Straube A, Pfaffenrath V, Stefenelli U, Ceballos-Baumann A (2009) Botulinum toxin as preventive treatment for migraine: a randomized double-blind study. Eur Neurol 62:204–211. doi:10.1159/000228987 CrossRefPubMedGoogle Scholar
  46. Rollnik JD, Tanneberger O, Schubert M, Schneider U, Dengler R (2000) Treatment of tension-type headache with botulinum toxin type A: a double-blind Placebo-Controlled Study. Headache J Head Face Pain 40:300–305CrossRefGoogle Scholar
  47. Sandrini G, Perrotta A, Tassorelli C, Torelli P, Brighina F, Sances G, Nappi G (2011) Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. J Headache Pain 12:427–433. doi:10.1007/s10194-011-0339-z CrossRefPubMedPubMedCentralGoogle Scholar
  48. Schwedt TJ (2014) Chronic migraine. BMJ 348:g1416. doi:10.1136/bmj.g1416 CrossRefPubMedGoogle Scholar
  49. Silberstein et al (2000) Botulinum toxin type A as a migraine preventive treatment. Headache 40:445–450CrossRefPubMedGoogle Scholar
  50. Welch MJ, Purkiss JR, Foster KA (2000) Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 38:245–258CrossRefPubMedGoogle Scholar
  51. Wollmer MA et al (2012) Facing depression with botulinum toxin: a randomized controlled trial. J Psychiatr Res 46:574–581. doi:10.1016/j.jpsychires.2012.01.027 CrossRefPubMedGoogle Scholar
  52. Yang M, Rendas-Baum R, Varon SF, Kosinski M (2011) Validation of the Headache Impact Test (HIT-6™) across episodic and chronic migraine. Cephalalgia 31(3):357–367. doi:10.1177/0333102410379890 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Wien 2016

Authors and Affiliations

  • Katja Kollewe
    • 1
  • Claus M. Escher
    • 1
  • Dirk U. Wulff
    • 2
  • Davood Fathi
    • 1
    • 3
    • 4
  • Lejla Paracka
    • 1
  • Bahram Mohammadi
    • 4
    • 5
  • Matthias Karst
    • 6
  • Dirk Dressler
    • 1
  1. 1.Department of Neurology, Movement Disorder SectionHannover Medical SchoolHannoverGermany
  2. 2.Max Planck Institute for Human DevelopmentBerlinGermany
  3. 3.Brain and Spinal Injury Research CenterTehran University of Medical SciencesTehranIran
  4. 4.International Neuroscience InstituteHannoverGermany
  5. 5.Department of NeurologyUniversity of LübeckLübeckGermany
  6. 6.Department of Anaesthesiology, Pain ClinicHannover Medical SchoolHannoverGermany

Personalised recommendations